CN110108673A - 用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 - Google Patents
用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 Download PDFInfo
- Publication number
- CN110108673A CN110108673A CN201910326370.7A CN201910326370A CN110108673A CN 110108673 A CN110108673 A CN 110108673A CN 201910326370 A CN201910326370 A CN 201910326370A CN 110108673 A CN110108673 A CN 110108673A
- Authority
- CN
- China
- Prior art keywords
- pipeline
- cholesterol
- detection module
- detection
- module
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 135
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 66
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 45
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 45
- 239000002245 particle Substances 0.000 title claims abstract description 40
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 36
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 14
- 230000008676 import Effects 0.000 claims abstract description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- -1 alkyl phenol Chemical compound 0.000 claims description 13
- 238000004140 cleaning Methods 0.000 claims description 13
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 12
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 6
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 6
- 102000003992 Peroxidases Human genes 0.000 claims description 6
- 108010055297 Sterol Esterase Proteins 0.000 claims description 6
- 102000000019 Sterol Esterase Human genes 0.000 claims description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 6
- 239000002699 waste material Substances 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 4
- FDIPWBUDOCPIMH-UHFFFAOYSA-N 2-decylphenol Chemical compound CCCCCCCCCCC1=CC=CC=C1O FDIPWBUDOCPIMH-UHFFFAOYSA-N 0.000 claims description 3
- FIWYWGLEPWBBQU-UHFFFAOYSA-N 2-heptylphenol Chemical compound CCCCCCCC1=CC=CC=C1O FIWYWGLEPWBBQU-UHFFFAOYSA-N 0.000 claims description 3
- ABMULKFGWTYIIK-UHFFFAOYSA-N 2-hexylphenol Chemical group CCCCCCC1=CC=CC=C1O ABMULKFGWTYIIK-UHFFFAOYSA-N 0.000 claims description 3
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical compound CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 claims description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 3
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 description 10
- 108010007622 LDL Lipoproteins Proteins 0.000 description 10
- 102000007330 LDL Lipoproteins Human genes 0.000 description 10
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000010152 Huntington disease-like 3 Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/01—Arrangements or apparatus for facilitating the optical investigation
- G01N21/15—Preventing contamination of the components of the optical system or obstruction of the light path
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
- G01N21/51—Scattering, i.e. diffuse reflection within a body or fluid inside a container, e.g. in an ampoule
-
- G01N15/075—
Abstract
Description
项目名称 | 重复性(CV) |
HDL-P | 3.8% |
LDL-P | 2.6% |
Lpa-P | 5.7% |
IDL-P | 4.6% |
VLDL-P | 4.2% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910326370.7A CN110108673A (zh) | 2019-04-23 | 2019-04-23 | 用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910326370.7A CN110108673A (zh) | 2019-04-23 | 2019-04-23 | 用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110108673A true CN110108673A (zh) | 2019-08-09 |
Family
ID=67486229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910326370.7A Pending CN110108673A (zh) | 2019-04-23 | 2019-04-23 | 用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110108673A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112798481A (zh) * | 2020-10-27 | 2021-05-14 | 美康生物科技股份有限公司 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633168A (en) * | 1995-06-07 | 1997-05-27 | Glasscock; Larry M. | Controlled dispersion flow analysis system |
US20150146205A1 (en) * | 2012-06-16 | 2015-05-28 | Atherotech,Inc. | Measurement of serum lipoproteins |
CN107561297A (zh) * | 2017-08-25 | 2018-01-09 | 美康生物科技股份有限公司 | 用于血脂分型检测的试剂 |
CN108490204A (zh) * | 2011-09-25 | 2018-09-04 | 赛拉诺斯知识产权有限责任公司 | 用于多重分析的系统和方法 |
CN109152558A (zh) * | 2016-05-18 | 2019-01-04 | 医疗光电设备有限公司 | 血液中脂质浓度计测装置及其操作方法 |
-
2019
- 2019-04-23 CN CN201910326370.7A patent/CN110108673A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633168A (en) * | 1995-06-07 | 1997-05-27 | Glasscock; Larry M. | Controlled dispersion flow analysis system |
CN108490204A (zh) * | 2011-09-25 | 2018-09-04 | 赛拉诺斯知识产权有限责任公司 | 用于多重分析的系统和方法 |
US20150146205A1 (en) * | 2012-06-16 | 2015-05-28 | Atherotech,Inc. | Measurement of serum lipoproteins |
CN109152558A (zh) * | 2016-05-18 | 2019-01-04 | 医疗光电设备有限公司 | 血液中脂质浓度计测装置及其操作方法 |
CN107561297A (zh) * | 2017-08-25 | 2018-01-09 | 美康生物科技股份有限公司 | 用于血脂分型检测的试剂 |
Non-Patent Citations (1)
Title |
---|
潘柏申 等: "《检验医学进展》", 31 August 2018, 中华医学电子音像出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112798481A (zh) * | 2020-10-27 | 2021-05-14 | 美康生物科技股份有限公司 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chien et al. | Urine sediment examination: a comparison of automated urinalysis systems and manual microscopy | |
US6251615B1 (en) | Cell analysis methods | |
US3740143A (en) | Automatic apparatus for determining the percentage population of particulates in a medium | |
US9568488B2 (en) | Biological sample analyzing apparatus | |
US20120214224A1 (en) | Flow based clinical analysis | |
US10197492B2 (en) | Measurement of serum lipoproteins | |
Oldaker et al. | Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma | |
CN107402296A (zh) | 一种循环肿瘤细胞的免疫荧光染色及判读方法 | |
ATE278961T1 (de) | Verfahren zum nachweis und zur identifizierung, zählung und bestätigung von zirkulierenden krebszellen und/oder hämatologischen vorläuferzellen in vollblut | |
WO2021036105A1 (zh) | 一种用于分析CD1c+树突状细胞亚群表型和功能的组合配方试剂盒及其应用 | |
US20170322135A1 (en) | Measurement of serum lipoproteins | |
CN110186836A (zh) | 循环肿瘤细胞分离分析与分型计数的光流控流式细胞仪 | |
CN107561297A (zh) | 用于血脂分型检测的试剂 | |
CN107167616A (zh) | 血型检测方法及装置 | |
CN110108673A (zh) | 用于同时检测脂蛋白亚组分胆固醇和脂蛋白颗粒浓度的检测系统 | |
KR20070012413A (ko) | 샘플 중 지질 입자 분포를 측정하기 위한 광학적 방법 및시스템 | |
US5284773A (en) | Determination of lipoprotein concentration in blood by controlled dispersion flow analysis | |
JPH09329597A (ja) | 尿沈渣検査システム | |
CN104749108B (zh) | 血中丝虫幼虫的检测方法、血液分析装置和信息处理系统 | |
CN108982839A (zh) | 基于免疫磁珠和流式细胞仪的循环肿瘤细胞检测方法 | |
CN108627637A (zh) | 一种血小板聚集功能检测系统及方法 | |
CN104297327B (zh) | 一种采用微流控芯片分析血清脂蛋白亚型精细亚组分的方法 | |
US20080261313A1 (en) | Apo B measurement system and method | |
De Haene et al. | Comparison of triglyceride concentration with lipemic index in disorders of triglyceride and glycerol metabolism | |
CN111528219B (zh) | 一种用于t淋巴细胞亚群计数标准物质的冻干保护剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 330000 the three or four tier of science and technology 2 building, electronic information industry park, Nanchang economic and Technological Development Zone, Nanchang, Jiangxi. Applicant after: Jiangxi Meikang Shengde Biotechnology Co.,Ltd. Address before: 330000 the three or four tier of science and technology 2 building, electronic information industry park, Nanchang economic and Technological Development Zone, Nanchang, Jiangxi. Applicant before: JIANGXI WEIRUI BIOTECHNOLOGY Co.,Ltd. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190809 |